MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

31.09 -5.84

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

30.74

Massimo

33.1

Metriche Chiave

By Trading Economics

Entrata

-16M

-97M

Vendite

361K

361K

Margine di Profitto

-26,807.202

Dipendenti

437

EBITDA

-17M

-110M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+127.27% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-68M

3.1B

Apertura precedente

36.93

Chiusura precedente

31.09

Notizie sul Sentiment di mercato

By Acuity

100%

0%

365 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 lug 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 lug 2025, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 lug 2025, 21:04 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 lug 2025, 23:43 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 lug 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 lug 2025, 22:47 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 lug 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 lug 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 lug 2025, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 lug 2025, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 lug 2025, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lug 2025, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lug 2025, 22:30 UTC

Discorsi di Mercato
Utili

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 lug 2025, 22:20 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

17 lug 2025, 22:20 UTC

Discorsi di Mercato
Utili

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 lug 2025, 22:04 UTC

Discorsi di Mercato
Utili

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 lug 2025, 22:03 UTC

Acquisizioni, Fusioni, Takeovers

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 lug 2025, 21:58 UTC

Discorsi di Mercato
Utili

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 lug 2025, 21:57 UTC

Utili

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lug 2025, 21:47 UTC

Utili

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 lug 2025, 21:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 lug 2025, 21:45 UTC

Discorsi di Mercato

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 lug 2025, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 lug 2025, 21:22 UTC

Acquisizioni, Fusioni, Takeovers

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lug 2025, 21:05 UTC

Utili

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lug 2025, 21:04 UTC

Acquisizioni, Fusioni, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 lug 2025, 21:02 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lug 2025, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

17 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

127.27% in crescita

Previsioni per 12 mesi

Media 72.5 USD  127.27%

Alto 97 USD

Basso 36 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

10

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

365 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.